Tirzepatide in Obese Patients with CKD and Type 2 Diabetes

Introduction to Tirzepatide

• The American Journal of Kidney Diseases recommends tirzepatide as a reasonable option for patients with type 2 diabetes and CKD who have not achieved glycemic targets despite metformin and SGLT2 inhibitor use, or who cannot tolerate those medications 1

Dosing and Administration

• The American Journal of Kidney Diseases states that no dose adjustment is required for tirzepatide across all stages of CKD, including patients on hemodialysis 1
• The initial dose of tirzepatide is 2.5 mg subcutaneously once weekly, with titration by 2.5 mg every 4 weeks to 10 mg or 15 mg based on response and tolerability 2

Clinical Efficacy

• The Kidney Disease Outcomes Quality Initiative guidelines recommend tirzepatide as a first-line or second-line treatment option for patients with type 2 diabetes and CKD 1
• The American Diabetes Association emphasizes that weight management is an impactful component of glucose-lowering management in type 2 diabetes, with tirzepatide showing very high efficacy 4

Safety and Monitoring

• The American Journal of Kidney Diseases notes that tirzepatide has a reassuring renal safety profile with no increased risk of adverse renal events 1
• Common adverse effects of tirzepatide include gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation 2

Guideline-Based Positioning

• The 2025 KDOQI guidelines recommend tirzepatide as a reasonable option for patients with type 2 diabetes and CKD who have not achieved glycemic targets despite metformin and SGLT2 inhibitor use, or who cannot tolerate those medications 1
• The American College of Cardiology and the American Heart Association may also recommend tirzepatide for patients with type 2 diabetes and CKD, although specific guidelines are not provided in the article 1